Publication | Closed Access

Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial

UrologySurgical OncologyGenitourinary CancerMedicineTemsirolimus Vs SorafenibCancer TreatmentOncologyRadiation OncologySecond Line TherapyIntorsect Trial